IMUC Insider Trading Activity and SEC Form 4 Filings
IMUC insider trading summary
No open-market insider purchases or sales of ImmunoCellular Therapeutics, Ltd. (IMUC) have been reported on SEC Form 4 in the past 12 months.
Latest IMUC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 30, 2015 | Andrew Gengos | President and CEO | Buy | $4K (10,000 @ $0.43) |
| Feb 18, 2015 | David Fractor | VP of Finance | Buy | $10K (16,667 @ $0.60) |
| Feb 18, 2015 | Andrew Gengos | President and CEO | Buy | $25K (41,333 @ $0.60) |
| Feb 18, 2015 | Anthony Gringeri | Senior VP Strategic Resources | Buy | $18K (30,000 @ $0.60) |
| Aug 21, 2014 | Anthony Gringeri | Senior VP Strategic Resources | Buy | $10K (11,000 @ $0.91) |
| Aug 14, 2014 | Andrew Gengos | President and CEO | Buy | $9K (10,000 @ $0.90) |
| Dec 23, 2013 | Anthony Gringeri | Senior VP Strategic Resources | Buy | $0 (25,000 @ $0.00) |
| Dec 20, 2013 | Gary Titus | Director | Buy | $78 (100 @ $0.78) |
| Dec 20, 2013 | Gary Titus | Director | Buy | $14K (17,900 @ $0.78) |
| Dec 18, 2013 | Andrew Gengos | President and CEO | Buy | $19K (27,000 @ $0.72) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.